The April 18th White House executive order on psychedelics is best understood not as a legalization measure, but a policy shift accelerating treatment development. The Administration framed it explicitly as a mental health initiative—“Removing barriers to psychedelic drugs“—for serious mental illnesses like PTSD, depression, and addiction
Veterans and VHA
The Executive Office (EO) explicitly frames psychedelics as a response to treatment-resistant mental illness in veterans—PTSD, suicide, depression, and substance use disorders. Military veterans are the primary clinical population around which these federal psychedelic initiatives are organized. The Veterans Health Administration (VHA) is a proving ground—a structured, federally-integrated system where psychedelic therapies can be studied, validated, and potentially deployed under tight controls.
The EO directs coordination between the Department of Veterans Affairs and agencies such as the NIH and the FDA to expand clinical trials and data sharing. The EO encourages veteran participation in clinical trials or expanded access programs, positioning the VA as a controlled- access environment.
Veterans with refractory PTSD, suicidal thoughts, substance abuse, or depression—difficult populations to treat with conventional pharmacotherapy—are prioritized.
The President’s order directs federal agencies to facilitate clinical trial participation, expand access pathways such as Right-to-Try mechanisms, and prioritize regulatory review. This creates real momentum—compressing development timelines, signaling to regulators, researchers, and investors that psychedelics are a federal priority. However, it does not alter statutory requirements for approval: the FDA still requires substantial evidence of safety and efficacy.
The immediate regulatory impact of the EO is already visible. Three companies—Compass Pathways (COMP360 psilocybin for treatment-resistant depression), Usona Institute (psilocybin for major depressive disorder), and Transcend Therapeutics (methylone for PTSD)—received FDA Commissioner’s National Priority Vouchers following the EO. In parallel, the FDA permitted clinical development of DemeRx’s DMX-1001 (oral noribogaine hydrochloride) for treating alcohol use disorder, marking the first U.S. clinical pathway for an ibogaine-derived therapy.
Comments From Experts
At the White House signing and in subsequent comments, Nora Volkow, MD, director of NIDA, said while patient-reported experiences and early benefit signals should be considered, these therapies remain investigational and must be evaluated through meticulous scientific frameworks. Volkow reinforces that the executive order should accelerate research, not substitute for it.
The more pointed caution has come from Yale Chairman, John Krystal, MD, whose critique is rooted in FDA proof standards. His central argument is that psychedelics, despite their promise, are not yet supported by the level of FDA evidence required for routine clinical use, and current policy momentum risks advancing them faster than the data could justify. Krystal’s concern is that psychedelic research deficiencies and expectancy bias may produce overestimates of efficacy that cannot hold up under more rigorous phase III conditions.
Whether this EO push translates into safe, effective, and scalable therapies will depend on whether the field can meet the same proof-of-concept criteria that govern prior approvals. The history of esketamine suggests standards for highly promising therapies should be demanding, but can be met fully before being responsibly integrated into clinical practice.
Ten FDA Proof Issues for Psychedelics
Psychedelic studies are vulnerable because patients and clinicians usually “know” if they received the placebo or psychedelic treatment: non-hallucinogenic drugs don’t cause hallucinations. Even the use of low-dose psychedelics introduces its own issues. However, the FDA does adapt evidentiary expectations for serious conditions, unmet needs, and novel mechanisms. For example, the Breakthrough Therapy designation often allows the FDA to tolerate imperfect blinding.
Closely related is the problem of the effect size. Early studies often reported large effects, but were derived from small, highly supervised settings and lacked independent replication. The FDA’s “substantial evidence” standard typically requires consistent results across multiple trials and populations. However, psychiatry approvals (including Spravato) have allowed mixed or modest effect size.
Durability remains unresolved. Psychedelic therapies can produce rapid improvements after one or a few sessions, but the persistence of these effects is unestablished. FDA approval in psychiatry emphasizes acute efficacy, as well as maintenance of benefit and relapse prevention. With limited longitudinal data, it is unclear how often psychedelics provide sustained vs. transient improvements.
Generalizability complicates interpretation. Trial populations are highly selected by experts, excluding individuals with bipolar disorder, psychosis, and substance use, and psychedelic treatments are given in structured, resource-intensive settings. This raises concerns about generalizability to broader populations.
Drug–drug interaction complexity needs to be considered. Psychiatric patients rarely take only one medicine; they are often treated with SSRIs, antipsychotics, and mood stabilizers, which may alter psychedelic effects. They may also use cannabis and other drugs of abuse. What are the data on interaction effects?
Many research trials require discontinuing existing meds, and patient improvement could partially reflect the removal of ineffective or harmful regimens, not just the psychedelic effect.
Psychedelic treatments are closely linked to psychotherapy, environment, and patient expectations. The FDA requires evidence the drug itself contributes materially to outcomes. When benefit reflects both pharmacologic and non-pharmacologic factors, attribution becomes uncertain, complicating regulatory evaluation and clinical implementation.
Safety may be the most fundamental concern. Current datasets are small, often involving only a few hundred patients with limited follow-up, reducing the ability to detect rare or delayed adverse events—particularly persistent anxiety, affective instability, or precipitation of mania or psychosis. The FDA typically expects larger safety databases for central nervous system (CNS) medicines.
Psychedelic dose standardization as well as treatment regimen definition are additional safety issues. Manufacturing and formulation consistency and stability under clinical conditions are particularly relevant for naturally-derived or complex compounds. FDA will likely expect a clearly-defined dose-response relationship, justification for the session number, evidence that the treatment regimen is optimal, not arbitrary, and the adoption of pre-trial primary endpoints.
Even in a therapeutic context, abuse liability and scheduling implications cannot be ignored. The FDA will coordinate with the DEA on scheduling decisions after a formal assessment of abuse potential, diversion risk, and reinforcing properties. This is particularly relevant for compounds with similarities to drugs of abuse like MDMA analogs.
Psychedelics Essential Reads
Lessons From Ketamine
Consider Spravato, a novel rapid-acting CNS intervention whose development from Ketamine benefited from expedited regulatory pathways. Its approval nonetheless required multiple randomized controlled trials, replication across studies, and a substantial safety database. Even then, evidence remained debated, effect sizes were modest, and the drug was approved with a stringent Risk Evaluation and Mitigation Strategy (REMS) mandating in-clinic administration and direct patient monitoring.
Long-term psychedelic safety remains unresolved. Existing datasets are limited in size and duration, adding to uncertainty around the incidence of persistent perceptual disturbances, subtle cognitive or affective changes, and delayed emergence of mood instability, including mania-spectrum disorders.
The REMS model for Spravato has proven that in-clinic administration monitoring requirements, distribution restrictions, and long-term follow-up works.
A central regulatory question for psychedelics is whether a comparable REMS-like infrastructure—requiring supervised dosing sessions, trained personnel, and post-administration monitoring—can be implemented in real-world practice. If such a system proves operationally infeasible, approval may be accompanied by restrictive access conditions.
Conclusion
The EO accelerates the pathway to development, but FDA approval requirements are rigorous demonstration of safety and efficacy through randomized controlled trials.
In practical terms, the Executive Order should quickly expand access to investigational psychedelics through Right-to-Try pathways, particularly for patients with serious or treatment-resistant illnesses without access to clinical trials. However, such access does not substitute for the evidentiary standards required by the FDA. The EO signals a new priority to NIH, which will influence funding allocation and may affect reviewers’ mindsets. Anchoring in the VA system provides an important real-world data infrastructure, large, centralized patient populations, and built-in longitudinal follow-up. This VA partnership could be the big game-changer, materially accelerating evidence generation.